Excel Biosystems Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 25-05-2024
- Paid Up Capital ₹ 0.18 M
as on 25-05-2024
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.81 M
as on 25-05-2024
- Revenue -5.21%
(FY 2020)
- Profit -38.57%
(FY 2020)
- Ebitda -0.94%
(FY 2020)
- Net Worth 11.40%
(FY 2020)
- Total Assets 0.82%
(FY 2020)
About Excel Biosystems
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.18 M.
The company currently has active open charges totaling ₹1.81 M.
Neeru Sharma, Sanjeev Roy, Shyam Sharma, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239DL2004PTC125234
- Company No.
125234
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- LocationNew Delhi, Delhi
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Excel Biosystems Private Limited offer?
Excel Biosystems Private Limited offers a wide range of products and services, including Ayurvedic Powder and Medicinal Herbs, Herbal Powder, Homeopathic Medicines & Remedies, Homeopathic Drugs, Ayurvedic,Herbal Products & Medicine, Ayurvedic Immunity Booster, Common Disease Medicines, Antiseptic Mouthwashes, Ayurvedic, Herbal Oils and Cosmetics, Ayurvedic Cosmetics.
Who are the key members and board of directors at Excel Biosystems?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeru Sharma  | Director | 18-May-2004 | Current |
| Sanjeev Roy | Additional Director | 17-Mar-2004 | Current |
| Shyam Sharma | Director | 17-Mar-2004 | Current |
| Ritu Roy | Director | 18-May-2004 | Current |
Financial Performance of Excel Biosystems.
Excel Biosystems Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 5.21% decrease. The company also saw a substantial fall in profitability, with a 38.57% decrease in profit. The company's net worth Soared by an impressive increase of 11.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Excel Biosystems?
In 2017, Excel Biosystems had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 21 Jun 2023 | ₹1.81 M | Open |
How Many Employees Work at Excel Biosystems?
Unlock and access historical data on people associated with Excel Biosystems, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Excel Biosystems, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Excel Biosystems's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
